Q-omics provides the consensus-scored RNA5SP379 profile across patient tissues and cancer cell-line models. RNA5SP379 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RNA5SP379 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, RNA5SP379 RNA expression shows 5,791 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight BRCA, KIRP, and OV as cancer lineages where RNA5SP379 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP379 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP379 survival associations across molecular data types. RNA5SP379 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP379 RNA expression–survival associations across cancer types. High RNA5SP379 expression shows unfavorable associations in LUSC, READ and STAD, but favorable associations in BRCA, ACC and DLBC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for RNA5SP379 RNA expression.
This table summarizes RNA5SP379 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP379. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP379 shows lower tumor expression in THCA and higher tumor expression in KIRP, BLCA and STAD. The KIRP box plot shows higher RNA5SP379 RNA expression in tumor versus normal tissue (log2 FC = +0.291, t-test p < 0.001).
This table shows molecular features associated with RNA5SP379 in patient tissues and cancer cell lines. In patient samples, RNA5SP379 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
